tran3x

multidimensional depigmenting solution by mesoestetic®

multidimensional depigmenting program
for unique efficient results
with tranexamic acid

mesoestetic®

tran3x

multidimensional depigmenting program for unique efficient results

The new **mesoestetic®** program is based on the power of tranexamic acid, which has a depigmenting efficacy of high skin tolerance and acts on the vascular[1] and inflammatory[2] component that characterises multiple hyperpigmentations. Through this action, it can counteract post-inflammatory pigmentation after aggressive treatments[3].

Tranexamic acid: 3 synergistic dimensions

Its innovative mechanism of action acts on keratinocytes[4] *(fig. 1)*, inhibiting the release of melanocyte stimulating agents and factors triggering the inflammatory and vascular process: prostaglandins (PG)[5-8] and endothelin-1 (ET-1)[9-11].



(fig. 1)

1 vascularisation

It reduces the excessive vascularisation that characterises some recurrent hyperpigmentations, such as melasma.

2 inflammation

It acts on the inflammatory process that occurs after external aggressions, skin lesions (acne, scars) or medical-cosmetic treatments, such as laser or photodepilation.

3 pigmentation

It regulates effectively the melanogenesis process by reducing the amount and activity of tyrosinase, avoiding proliferation of melanocytes and reducing their dendricity.

tran3x is an innovative, modular program that combines several treatment categories for a flexible, integral depigmentation action that allows to act on hyperpigmentation at several depths. Minimally invasive.

Modular program

It allows combining different methods to modulate depigmenting intensity.

Multilevel solution

It allows to act on pigmentation at different depths of the epidermis:



Transcutaneous solution

High concentrations of active ingredients that applied topically by microneedling (or other vehiculisation techniques) allow to approach the active ingredient to the treatment focus.

Peeling

A solution with an acid pH with a formula combining depigmenting active ingredients to act integrally on the visible pigmentation present in the uppermost skin layers.

Products for professional use

50 mL bottle

mesopeel® **melanostop tran3x**

20% azelaic + 10% resorcinol + 6% phytic + 3% tranexamic

Depigmenting peeling with a complex formula that accelerates epidermis renewal for removal of the melanin built up on the surface. It provides a visible improvement in tone and luminosity.

Its formula provides a perfect balance between efficacy and tolerance.

5 mL x 5

c.prof 210 depigmentation solution

Vitamin C + idebenone + NAG (n-acetyl glucosamine) + tranexamic acid

Transcutaneous solution that acts regulating melanin production and removing the melanin present in epidermal cells, responsible for visible pigmentation. It contains antioxidant agents that regulate melanin overproduction.

Compatible with multiple vehiculisation systems:

microneedling · rollers · ultrasound · cavitation · radiofrequency · iontophoresis

Indications of tran3x program

> As modular depigmentation treatment

In solar, senile lentigo, ephelides and even PIH*, of various severities.
Pigmentation in body areas, such as friction areas, armpits, inner thigh.
Flexible, minimally invasive protocols.

> As post-laser treatmen

To prevent the PIH* rebound caused b
and dark phototypes[2], and improve ar
outcomes.

characteristics

· Water-alcohol solution of pH 1.3
· Removes the melanin built up in the horny layer, accelerating renewal of the skin surface.
· Regulates melanin overproduction by acting on the melanogenesis activation mechanisms.
· Provides a more even skin tone, reducing dark spots visibly.

indications

> Mild or moderate hyperpigmentation, such as solar lentigo or ephelides, or PIH* in fair to medium phototypes (I-III) .

> Photoaging

> Suitable for treating body pigmentations.

ESTIMATED TIME PER SESSION
15 min

TIME OF EXPOSURE BY AREA**:
face 5 min
neck 2 min
body 5 to 7 min

TIME BETWEEN SESSIONS
15 days

RECOMMENDED SESSIONS
5 sessions

APPLICATION
topical

characteristics

. Sterile solution with a physiological pH.
· It allows removing and regulating the excess of pigmentation that causes dark spots on the skin.
· It improves skin tone, enhancing a regular pigmentation and greater luminosity.
. Its application by microneedling enhances cell renewal and induces the synthesis of new collagen.

indications

> Moderate hyperpigmentations, such as solar or senile lentigo, or PIH* in fair to medium phototypes (I-III).

> Suitable for treating localised areas of resistant pigmentation.

ESTIMATED TIME PER SESSION
30 min

TIME BETWEEN SESSIONS
15 days

RECOMMENDED SESSIONS
5 sessions

APPLICATION
transcutaneous

ent

ed by laser in patients with medium
e and enhance depigmenting

> As maintenance treatment

After treatment with **cosmelan®** / **dermamelan®**, to maintain pigmentation under control and enhance the outcomes, due to the recurrent and chronic nature of diseases such as melasma.

*Post-inflammatory hyperpigmentation. Pigmentation due to skin lesions: acne, scars, chemical peels, laser, upper lip depilation, etc.
**Recommended times of exposure before product neutralisation.

Products for home use

Last-generation home depigmentation treatment made up of two synergistic references: **an intensive concentrate and a gel cream**. Its joint daily use provides continuous, gradual reduction of excess melanin and integral action on all melanogenesis process stages.

Complementary to professional depigmentation treatments to enhance and prolong its results.

30 mL

DERMATOLOGICALLY TESTED

50 mL

DERMATOLOGICALLY TESTED

melan tran3x
intensive depigmenting concentrate

Intensive depigmenting serum that acts on dark spots, removing the melanin formed and regulating pigment overproduction in its origin.
Ultra-light texture.

melan tran3x
daily depigmenting gel cream

Depigmenting cream gel that acts gradually reducing spots and preventing their reappearance.
Fast-absorbing cream gel texture.

3% tranexamic acid

5% enzymacid complex
mandelic acid
salicylic acid
lactic acid
enzyme active ingredient

1.5% hydroxyacid complex
salicylic acid
lactic acid

2% tyr control complex
kojic acid + biotechnologic plankton extract: inhibits tyrosinase activity
tyr control peptide: control of tyrosinase synthesis
alanine: stabilises dopachrome

5% niacinamide[14]

3% niacinamide[14]

Results *in vivo*

mesopeel® melanostop tran3x



Results obtained after 5 sessions of **mesopeel**® melanostop tran3x every 15 days.[15].

c.prof 210 depigmentation solution



Treatment of 5 sessions by microneedling with **m.pen** [pro] **by mesoestetic**® [15]

mesopeel® melanostop tran3x + **c.prof 210** depigmentation solution



Outcomes obtained after 4 sessions of treatment with **mesopeel**® melanostop tran3x and **c.prof 210** depigmentation solution by microneedling with **m.pen** [pro] **by mesoestetic**®. 15 days between sessions.[15]

tran3x

multidimensional depigmenting solution

Modular program for the treatment of skin hyperpigmentation.

Combines peeling, transcutaneous solution and home treatment.

With tranexamic acid, an active ingredient that provides a perfect balance between efficacy and tolerance.

Compatible with other professional depigmentation treatments.

(1) Na JI, Choi SY, Yang SH, Choi HR, Kang HY, Park KC. Effect of tranexamic acid on melasma: a clinical trial with histological evaluation. J Eur Acad Dermatol Venereol. 2013;27(8):1035-9. **(2)** Sirithanabadeekul P, Srieakpanit R. Intradermal tranexamic acid injections to prevent post-inflammatory hyperpigmentation after solar lentigo removal with a Q-switched 532-nm Nd:YAG laser. J Cosmet Laser Ther. 2018;:1-7. **(3)** Taraz M, Niknam S, Ehsani AH. Tranexamic acid in treatment of melasma: A comprehensive review of clinical studies. Dermatol Ther. 2017;30(3) **(4)** Tse TW, Hui E. Tranexamic acid: an important adjuvant in the treatment of melasma. J Cosmet Dermatol. 2013;12(1):57-66. **(5)** Starner RJ, Mcclelland L, Abdel-malek Z, Fricke A, Scott G. PGE(2) is a UVR-inducible autocrine factor for human melanocytes that stimulates tyrosinase activation. Exp Dermatol. 2010;19(7):682-4. **(6)** Scott G, Leopardi S, Printup S, Malhi N, Seiberg M, Lapoint R. Proteinase-activated receptor-2 stimulates prostaglandin production in keratinocytes: analysis of prostaglandin receptors on human melanocytes and effects of PGE2 and PGF2alpha on melanocyte dendricity. J Invest Dermatol. 2004;122(5):1214-24. **(7)** Kabashima K, Sakata D, Nagamachi M, Miyachi Y, Inaba K, Narumiya S. Prostaglandin E2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells. Nat Med. 2003;9(6):744-9. **(8)** Deezagi A, Shomali S. Prostaglandin F-2α Stimulates The Secretion of Vascular Endothelial Growth Factor and Induces Cell Proliferation and Migration of Adipose Tissue Derived Mesenchymal Stem Cells. Cell J. 2018;20(2):259-266. **(9)** Kim SJ, Park JY, Shibata T, Fujiwara R, Kang HY. Efficacy and possible mechanisms of topical tranexamic acid in melasma. Clin Exp Dermatol. 2016;41(5):480-5. **(10)** Imokawa G, Yada Y, Miyagishi M. Endothelins secreted from human keratinocytes are intrinsic mitogens for human melanocytes. J Biol Chem. 1992;267(34):24675-80. **(11)** Imokawa G, Yada Y, Kimura M. Signalling mechanisms of endothelin-induced mitogenesis and melanogenesis in human melanocytes. Biochem J. 1996;314 (Pt 1):305-12. **(12)** Peterson RA, Krull PE, Finley P, Ettinger MG. Changes in antithrombin 3 and plasminogen induced by oral contraceptives. Am J Clin Pathol. 1970;53(4):468-73. **(13)** Kim EH, Kim YC, Lee ES, Kang HY. The vascular characteristics of melasma. J Dermatol Sci. 2007;46(2):111-6. **(14)** Hakozaki T, Minwalla L, Zhuang J, et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002;147(1):20-31. **(15)** Unidad Médica. Estudio in vivo de la capacidad despigmentante del método tran3x. mesoestetic Pharma Group, S.L. 2015.

DANSYS GROUP

info@dansysgroup.com | www.dansys.com

FOLLOW US

dansysgroup | Dansys Medical Group | Dansys Medical Group | Dansys Medical Group